Salmeterol Fluticasone Rotacap Franchise in Ahmedabad

Salmeterol 50mcg + Fluticasone 250mcg Rota Capsule Supplier in Mumbai

Asthma & COPD Capsule Distributor in Delhi

Respiratory Therapy Rotacap Manufacturer in Bangalore

Bronchodilator Anti-Inflammatory Rotacap Stockist in Hyderabad
Salmeterol Fluticasone Rotacap Exporter in Chandigarh

Home/Products /fluticasone-propionate-xinafoate-rota-cap

Flutialfa SF 250 Capsule

Composition : Salmeterol (50mcg) + Fluticasone Propionate (250mcg) Rota Caps

Dosage Form : Rota caps

Packaging Type : in a Bottle

Packaging : 30 Capsules

Price : ₹525/-

Please Contact For Best Price

Salmeterol 50mcg + Fluticasone Propionate 250mcg rota capsule is a combination inhalation therapy used for the effective management of asthma and COPD, providing improved airflow and symptom control.

Salmeterol acts as a long-acting beta-2 adrenergic bronchodilator, relaxing airway smooth muscles, while Fluticasone Propionate provides potent corticosteroid anti-inflammatory action, reducing airway inflammation and hyperresponsiveness.

This rotacap is commonly prescribed for maintenance therapy in persistent asthma, chronic bronchitis, and COPD, helping prevent exacerbations, reduce wheezing, and improve overall pulmonary function.

With clinically proven dual-action efficacy, patient-friendly administration, and consistent symptom relief, this formulation strengthens a respiratory therapy portfolio and supports sustained therapeutic demand.

Read More

About the Product

Salmeterol 50mcg + Fluticasone Propionate 250mcg rota capsule is a combination inhalation therapy used for the effective management of asthma and COPD, providing improved airflow and symptom control.

Salmeterol acts as a long-acting beta-2 adrenergic bronchodilator, relaxing airway smooth muscles, while Fluticasone Propionate provides potent corticosteroid anti-inflammatory action, reducing airway inflammation and hyperresponsiveness.

This rotacap is commonly prescribed for maintenance therapy in persistent asthma, chronic bronchitis, and COPD, helping prevent exacerbations, reduce wheezing, and improve overall pulmonary function.

With clinically proven dual-action efficacy, patient-friendly administration, and consistent symptom relief, this formulation strengthens a respiratory therapy portfolio and supports sustained therapeutic demand.

Flutialfa SF 250 Rota Capsule is indicated for the maintenance treatment of asthma and COPD. It helps in preventing bronchospasm, controlling inflammation, and improving lung function, as prescribed by a healthcare professional.

Common side effects may include throat irritation, hoarseness, cough, oral thrush, tremors, or mild palpitations. Rarely, systemic corticosteroid effects or cardiovascular effects may occur with prolonged use.

For inhalation use only. Use under strict medical supervision. Not intended for acute asthma attacks; a rescue inhaler should be used for sudden symptoms. Rinse mouth after each use to prevent oral infections.

Store in a cool, dry place below 25°C. Protect from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our Successful network today.

Quick Navigation

1500+ Products

Our Divisions

All Therapeutics

Disclaimer: Pharma Insights are based on operational standards as of March 2026. All territories are subject to availability and Revised Schedule M compliance.